The effect of cimetidine and ranitidine on serum high density lipoprotein subfractions.
Of the two major subfractions of high density lipoprotein (HDL), HDL2 cholesterol (HDL2-C) and not HDL3 cholesterol (HDL3-C) correlates negatively with coronary heart disease. To study the effect of cimetidine and ranitidine on HDL subfractions, 6 healthy males received cimetidine (600 mg bid) ranitidine (150 mg bid) and placebo (one tab bid) for 1 week each, in random order. Measurements of HDL cholesterol (HDL-C), HDL2-C, HDL3-C were made on day 7 of each week. Comparing cimetidine with placebo, HDL2-C/HDL-C, HDL2-C/total cholesterol and HDL2-C/HDL3-C increased significantly while HDL3-C/HDL-C decreased. There was no difference in HDL-C parameters between ranitidine and placebo. Cimetidine treatment results in redistribution of HDL subfractions in favour of HDL2. The mechanism is not H2-receptor antagonism as ranitidine had no such effect.
D000328:Adult; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood / Q000145:classification; D002927:Cimetidine / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000097:blood / Q000517:prevention & control; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood* / Q000145:classification; D008297:Male; D011897:Random Allocation; D011899:Ranitidine / Q000494:pharmacology*; D013997:Time Factors
D008076:Cholesterol, HDL; D008075:Lipoproteins, HDL; D002927:Cimetidine; D011899:Ranitidine; D002784:Cholesterol